Prescription rates for commonly used drugs before and after a prostate cancer diagnosis

Signe Benzon Larsen*, Christian Dehlendorff, Charlotte Skriver, Anton Pottegård, Søren Friis, Martin Andreas Røder, Klaus Brasso, Anne Katrine Duun-Henriksen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Purpose: To investigate differences in prescription rates of commonly used drugs among prostate cancer patients and cancer-free comparisons and between patients diagnosed with localized and non-localized disease. Methods: We conducted a register-based study including all men aged 50–85 years diagnosed with prostate cancer in Denmark from 1998 to 2015 and an age-matched cancer-free comparison cohort. We calculated the number of new and total prescriptions from three years before to three years after the date of diagnosis of the case for selected drug classes divided by the number of person-months and stratified by stage at diagnosis. Results: We included 54,286 prostate cancer patients and 249,645 matched comparisons. 30,712 patients were diagnosed with localized disease and 12,884 with non-localized disease. The rates of new prescriptions increased considerably among patients within the year before the diagnosis. Hereafter the rates varied between drug classes. For most drug classes, total prescription rates for patients and comparisons increased similarly in the study period. Total prescription rates varied between men with localized and non-localized disease for all drug classes apart from statins. Conclusion: Our findings indicate that a large proportion of prostate cancer cases are likely diagnosed during medical work-up for other reasons than prostate cancer. Increased rates occur within the last year before diagnosis and future studies on the interaction between drug use and prostate cancer should at least include a one year pre-diagnostic lag-time. Post-diagnostic prescription rates demonstrated an increased use of drugs most likely associated with the consequences of the disease.

TidsskriftCancer Causes and Control
Udgave nummer3
Sider (fra-til)417-428
StatusUdgivet - mar. 2022

Bibliografisk note

Funding Information:
The present study was funded by research grants from Kirsten and Freddy Johansens Fond and from the Peer Kølendorf Family Foundation. Anne Katrine Duun-Henriksen was funded by a research Grant from the Danish Cancer Society Scientific Committee (R204-A12.653).

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.


Dyk ned i forskningsemnerne om 'Prescription rates for commonly used drugs before and after a prostate cancer diagnosis'. Sammen danner de et unikt fingeraftryk.